Strategic Platform Nanobiotix is a late-stage nanotherapeutics company focused on physics-based radiotherapy enhancement (NBTXR3) and systemic delivery optimization (Curadigm Nanoprimer), presenting opportunities to partner with radiotherapy centers, oncology clinics, and pharma collaborations to expand adoption of their radiotherapy-boosting and drug-delivery platforms.

Key Partnerships Strategic collaboration with Johnson & Johnson on JNJ-1900 positions Nanobiotix as a royalty- and milestone-driven, capital-light opportunity for partners seeking oncology platform access, enabling BD teams to pursue co-development, licensing, and regional commercialization deals.

Clinical Momentum Recent Phase 1/early cohorts showing feasibility and meaningful local control at lower re-irradiation doses in NSCLC signal near-term milestones that can fuel investor and hospital interest, creating openings for site expansion, investigator-initiated trials, and payer discussions.

Global Footprint Headquartered in Paris with a U.S. affiliate in Cambridge, Nanobiotix has international reach that supports multi-territory sales strategies, regional clinical trials, and regulatory submissions, enhancing opportunities to engage global oncology networks and distribution partners.

Financial runway With a substantial funding pool and a cash runway extending into 2029 supported by recent financing, there is room to pursue rapid clinical expansion, joint ventures, and strategic investments in early-access programs and milestone-rich commercialization agreements.